

Europees Parlement

European Public health

Diyar Salih

Adviseur D66 Europees Parlement

D66

D66 In Europa

Europa is onze beste kans

Europa is niet veroordeeld tot zwakte. Integendeel! Keer op keer heeft Europa bewezen onze beste kans te zijn. We hebben de ingenieurs, de wetenschappers, de soldaten, de boeren, de ondernemers....



D66

D66 In Europa



D66


Gezondste generatie ooit ?




2024 - 2026





D66



D66 In Europa




D66 In Europa



D66


D66 In Europa



D66 In Europa




D66 In Europa



D66 In Europa

Seats 27




27

Committees 10 configurations [\[hide\]](#)

- Agriculture and fisheries
- Competitiveness
- Economic and financial affairs
- Education, youth, culture and sport
- Employment, social policy, health and consumer affairs
- Environment
- Foreign affairs
- General affairs
- Justice and home affairs
- Transport, telecommunications and energy

D66 In Europa



Er loopt veel door elkaar

- Eurocommissarissen zijn nationale politici
- Regeringsleiders hebben een politieke kleur
- MEPs allebei

All of the above komt neer op
belangenverstremgeling

D66 In Europa



D66

D66 In Europa

Home > Health > Healthcare

Draghi report touts path to pull EU pharma from 'slow agony'



Letta report highlights need for stronger healthcare sector



D66

D66 In Europa


STARTUP 28TH REGIME

What It Is




optional 28th EU-wide company legal form alongside 27 national ones, innovative startups/scaleups (deep-tech, R&D focus, IP ownership)

Key Known Features



single set of harmonised rules (corporate, insolvency, labour, tax), online incorporation, cross-border seamless operation, lower cost of failure/exits, attract pan-EU investment

Timeline & Status (Feb 2026)



under development - details TBD

EU PHARMACEUTICAL PACKAGE

Intended Goals



- boost innovation and competitiveness
- improve patient access/affordability
- secure supply chains
- environmental sustainability
- incentives for unmet needs

Equalising Application Procedures



- single submission via CTIS for multi-country trials
- harmonised assessment leading to single decision
- centralisation to reduce fragmentation/national differences shorter approval times (target 30-60 days)

Clinical Trials Reforms & Timelines



CTR fully applicable Jan 2025 (all trials transitioned to CTIS)



- pharma package agreement
- agreement 2025/adoption 2026/transition to 2028
- focus on faster approvals/parallel submissions
- incentives like extra data protection (up to 3 years) for EU multi-country trials/new active substances

D66

D66 In Europa

EHDS

Intended Goals

-  Empower individuals access/control electronic health data
-  Cross-border exchange for healthcare (patient summaries, ePrescriptions, imaging)
-  Secondary use for research/innovation/policy/pandemics
-  Foster single market for digital health/ EHR systems

Rollout Timeline



Why & Challenges

-  Patient empowerment
-  Legacy systems integration
-  Data sharing
-  Data quality/harmonization
-  Innovation
-  Governance/skills/funding gaps
-  Varying MS readiness

MDR INTENT

Intended Goals

-  higher patient safety
-  better transparency via EUDAMED
-  stronger clinical evidence
-  single EU market

Implementation Problems

-  notified bodies shortage
-  delays
-  higher costs and classifications

Ongoing Reforms (2025+)

-  extensions
-  more flexible clinical evidence
-  proportionality to risk
-  simplification proposal COM(2025)1023
-  support for SMEs and innovation

D66 In Europa

- **Biotech Act**
- **Safe Hearts Plan**

Health in All Policies

D66 In Europa

Q & A

D66

Het
kan
wél

D66